SCHEMBL337769

SCHEMBL337769

COC(=O)c1ncc(-c2ccccc2)nc1N(C)C(=O)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 4/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.40
IKBKB O14920 1/20 0.38
GAA P10253 1/20 0.38
ATR Q13535 3/20 0.38
PRKDC P78527 2/20 0.38
ERCC1 P07992 1/20 0.38
FEN1 P39748 1/20 0.38
ERCC4 Q92889 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336889 0.80 NPC1 (0.46) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL336273 0.76 TRPM8 (0.47) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL13629341 0.75 IKBKB (0.46) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL336653 0.74 ATR (0.53) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL6057019 0.74 PDCD1 (0.48) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL336700 0.73 SMN1; SMN2 (0.48) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL3461817 0.72 IKBKB (0.49) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL3462566 0.72 ATR (0.66) ATRPRKDC
SCHEMBL3461782 0.71 IKBKB (0.48) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2
SCHEMBL3460430 0.70 IKBKB (0.53) ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN ALDH1A1 108/4885KDM4E 248/4885HPGD 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.